Anti Inflammatory News and Research RSS Feed - Anti Inflammatory News and Research

FDA permits Sound Pharmaceuticals to start SPI-1005 clinical trial for treatment of Meniere's Disease

FDA permits Sound Pharmaceuticals to start SPI-1005 clinical trial for treatment of Meniere's Disease

Sound Pharmaceuticals is pleased to announce that it began enrolling a clinical trial to test SPI-1005 in the treatment of Meniere's Disease (MD). MD or idiopathic endolymphatic hydrops is an inner ear disease that involves episodic vertigo, sensorineural hearing loss, and tinnitus. [More]
Drug-microbe interactions may contribute to adverse effects, lessen effectiveness of NSAID

Drug-microbe interactions may contribute to adverse effects, lessen effectiveness of NSAID

A nonsteroidal anti-inflammatory drug (NSAID) changed the composition and diversity of gut microbes, which in turn shaped how the drug is broken down and ultimately, cut its effectiveness, according to an animal study from the Perelman School of Medicine at the University of Pennsylvania. [More]
Back pain becoming more common in children and adolescents

Back pain becoming more common in children and adolescents

According to a new literature review in the January issue of the Journal of the American Academy of Orthopaedic Surgeons, it's becoming more common for children and adolescents to seek medical care for back pain. Even with expensive, advanced tests like MRI scans, doctors may not be able to find the exact cause for the pain. [More]
Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. [More]
MUSC researchers receive $1.68 million NIH grant to study better treatment for chronic pancreatitis, diabetes

MUSC researchers receive $1.68 million NIH grant to study better treatment for chronic pancreatitis, diabetes

MUSC researchers received a $1.68 million National Institutes of Health grant to explore a better treatment for chronic pancreatitis, with the hopes that it also may shed light on a future cure for patients with type 1 diabetes. [More]
Natural dietary supplement Arthrem significantly reduces pain and stiffness in osteoarthritis patients

Natural dietary supplement Arthrem significantly reduces pain and stiffness in osteoarthritis patients

New Zealand company Promisia Integrative Limited, announced today significant positive results from a clinical trial on their natural dietary supplement Arthrem. The results have been published in the December 2015 issue of Clinical Rheumatology, a prestigious international peer reviewed medical journal. [More]
UAB's Undiagnosed Diseases Program finds answers for mysterious health issues

UAB's Undiagnosed Diseases Program finds answers for mysterious health issues

Stephanie and Christopher Smith have been on a long, difficult and often frustrating journey to find answers for the mysterious health issues of their children. It started 24 years ago when their third child, Gage, was born. Gage, his younger brother Aiden and then sister Mandalynn, now 13, all developed mysterious symptoms that mystified doctors. [More]
Body can control pathogen-induced inflammatory response, find Georgia State researchers

Body can control pathogen-induced inflammatory response, find Georgia State researchers

The body can control inflammatory response triggered by invasions of microbial pathogens, such as bacteria and viruses, a discovery that could lead to the development of new therapeutic agents for uncontrolled inflammation, according to researchers at Georgia State University. [More]
Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Diabetes is the leading cause of kidney failure, and scientists have found that infusing just a small dose of a cytokine, thought to help cause that failure, can instead prevent or reverse it. [More]
Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor. [More]
Large doses of vitamin A reduce severity of gastrointestinal disease in mice

Large doses of vitamin A reduce severity of gastrointestinal disease in mice

After observing that some gastrointestinal disease in premature human and mouse infants progresses only when certain immune system white blood cells go into inflammatory overdrive, Johns Hopkins researchers have found that giving large doses of vitamin A to mice converts those blood cells into inflammation suppressors and reduces the severity of the disease, compared to untreated mice. [More]
New treatment strategy may take pain away

New treatment strategy may take pain away

A brain region controlling whether we feel happy or sad, as well as addiction, is remodeled by chronic pain, reports a new Northwestern Medicine study. [More]
SciClone plans to pursue development of SGX942 in the Greater China market

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis. [More]
DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF). [More]
Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov announces more data from Phase III trial on the favorable blood pressure effects of KIT-302

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in the study. [More]
Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

A team of scientists at the University of Nebraska Medical Center (UNMC) and Longevity Biotech, Inc., has demonstrated that neuroprotection could be attained in preclinical models by a novel drug candidate that changes immune responses. [More]
Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer. [More]
Cancer drug may protect kidneys from damage caused by chemotherapy agent cisplatin

Cancer drug may protect kidneys from damage caused by chemotherapy agent cisplatin

A class of drugs used increasingly to help fight cancer may have the additional benefit of protecting the kidneys when packaged with the powerful chemotherapy agent cisplatin. [More]
Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals, an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical trial for its leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). [More]
Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company. [More]
Advertisement
Advertisement